A report released today by Vetr Inc. about Biogen Inc (NASDAQ:BIIB) ups the target price to $310.17
- Updated: March 19, 2017
Having a price of $276.09, Biogen Inc (NASDAQ:BIIB) traded -1.03% lower on the day. With the last close down -6.01% from the two hundred day average, compared with the S&P 500 Index which has increased 0.04% over the same time. The company has recorded a 50-day moving average of $283.74 and a 200-day moving average of $293.74. 3,140,208 shares of the stock were exchanged, up from an average trading volume of 1,648,340
Reporting a potential upside of 0.12%, Vetr Inc. bumped up the target of Biogen Inc (NASDAQ:BIIB) to $310.17
See Chart Below
Biogen Inc has a 52 week low of $223.02 and a 52 week high of $333.65 with a price-earnings ratio of 16.31 BIIB’s total market value is presently $0.
A total of 19 equity analysts have released a ratings update on BIIB. Six equity analysts rating the company a strong buy, eight equity analysts rating the company a buy, nine equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $333.47.
Brief Synopsis About Biogen Inc (NASDAQ:BIIB)
Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The Company's product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; BIIB061; BIIB054; BIIB067, and BIIB068.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.